Bellgardt Martin, Drees Dominik, Vinnikov Vladimir, Procopiuc Livia, Meiser Andreas, Bomberg Hagen, Gude Philipp, Vogelsang Heike, Weber Thomas Peter, Herzog-Niescery Jennifer
Department of Anaesthesiology and Intensive Care Medicine, St. Josef Hospital, Ruhr-University Bochum, Gudrunstraße 56, 44791, Bochum, Germany.
Department of Anaesthesiology, Intensive Care Medicine and Pain Medicine, Saarland University Medical Center, Kirrberger Straße 100, 66424, Homburg/Saar, Germany.
J Clin Monit Comput. 2018 Aug;32(4):623-627. doi: 10.1007/s10877-018-0138-z. Epub 2018 Apr 9.
The MIRUS™ system enables automated end-expired control of volatile anaesthetics. The device is positioned between the Y-piece of the breathing system and the patient's airway. The system has been tested in vitro and to provide sedation in the ICU with end-expired concentrations up to 0.5 MAC. We describe its performance in a clinical setting with concentrations up to 1.0 MAC. In 63 ASA II-III patients undergoing elective hip or knee replacement surgery, the MIRUS™ was set to keep the end-expired desflurane, sevoflurane, or isoflurane concentration at 1 MAC while ventilating the patient with the PB-840 ICU ventilator. After 1 h, the ventilation mode was switched from controlled to support mode. Time to 0.5 and 1 MAC, agent usage, and emergence times, work of breathing, and feasibility were assessed. In 60 out of 63 patients 1.0 MAC could be reached and remained constant during surgery. Gas consumption was as follows: desflurane (41.7 ± 7.9 ml h), sevoflurane (24.3 ± 4.8 ml h) and isoflurane (11.2 ± 3.3 ml h). Extubation was faster after desflurane use (min:sec): desflurane 5:27 ± 1:59; sevoflurane 6:19 ± 2:56; and isoflurane 9:31 ± 6:04. The support mode was well tolerated. The MIRUS™ system reliable delivers 1.0 MAC of the modern inhaled agents, both during mechanical ventilation and spontaneous (assisted) breathing. Agent usage is highest with desflurane (highest MAC) but results in the fastest emergence. Trial registry number: Clinical Trials Registry, ref.: NCT0234509.
MIRUS™ 系统可实现挥发性麻醉剂的呼气末自动控制。该设备位于呼吸系统的Y形接头与患者气道之间。该系统已在体外进行测试,并用于重症监护病房(ICU)的镇静,呼气末浓度可达0.5最低肺泡有效浓度(MAC)。我们描述了其在临床环境中浓度高达1.0 MAC时的性能。在63例接受择期髋关节或膝关节置换手术的美国麻醉医师协会(ASA)II - III级患者中,使用PB - 840 ICU呼吸机对患者进行通气时,将MIRUS™ 设置为使呼气末地氟烷、七氟烷或异氟烷浓度保持在1 MAC。1小时后,通气模式从控制模式切换为支持模式。评估达到0.5 MAC和1 MAC的时间、药物使用量、苏醒时间、呼吸功以及可行性。63例患者中有60例在手术期间能够达到并维持1.0 MAC。气体消耗量如下:地氟烷(41.7±7.9毫升/小时)、七氟烷(24.3±4.8毫升/小时)和异氟烷(11.2±3.3毫升/小时)。使用地氟烷后拔管更快(分钟:秒):地氟烷5:27±1:59;七氟烷6:19±2:56;异氟烷9:31±6:04。支持模式耐受性良好。MIRUS™ 系统在机械通气和自主(辅助)呼吸期间均能可靠地提供1.0 MAC的现代吸入麻醉剂。地氟烷(MAC最高)的药物使用量最高,但苏醒最快。试验注册号:临床试验注册中心,编号:NCT0234509 。